Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

NCT02318784 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT02318784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02318784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2015
Completion date
May 15, 2021
Enrollment
62 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine cancer